Pacira BioSciences Inc. (PCRX)
NASDAQ: PCRX
· Real-Time Price · USD
25.19
-0.62 (-2.40%)
At close: May 06, 2025, 3:59 PM
-2.40% (1D)
| Bid | 18.1 |
| Market Cap | 1.17B |
| Revenue (ttm) | 700.97M |
| Net Income (ttm) | -99.56M |
| EPS (ttm) | -2.15 |
| PE Ratio (ttm) | -11.72 |
| Forward PE | 6.77 |
| Analyst | Buy |
| Ask | 27.09 |
| Volume | 405,453 |
| Avg. Volume (20D) | 890,326 |
| Open | 25.98 |
| Previous Close | 25.81 |
| Day's Range | 24.94 - 26.09 |
| 52-Week Range | 11.16 - 31.67 |
| Beta | 0.56 |
About PCRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PCRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Pacira BioSciences Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+14.67%
Pacira BioSciences shares are trading higher after...
Unlock content with
Pro Subscription
4 weeks ago
-0.82%
Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.
3 weeks ago · seekingalpha.com
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN ActPCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which...
1 month ago · seekingalpha.com
Pacira BioSciences: Back On An Uptrend After Positive DevelopmentsPacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic,...
